Evidence map›Paper›PMID 42053886›Full record

ArticleCurrent medical science2026

Targeting the Gut Microbiota-Bile Acid-FXR Axis: The Therapeutic Mechanism of Yudantong Decoction in Cholestatic Liver Disease.

Xiao-Ming Wu, Lin-Yi Hou, Chang Liu, Yan Hu, Qiang He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiao-Ming WuDepartment of Traditional Chinese Medicine, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.ORCID http://orcid.org/0000-0001-5890-3104
Lin-Yi HouDepartment of Traditional Chinese Medicine, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.
Chang LiuDepartment of Traditional Chinese Medicine, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China.
Yan HuDepartment of Traditional Chinese Medicine, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China. huyan1302@sina.com.
Qiang HeDepartment of Traditional Chinese Medicine, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, 100045, China. heqiang@bch.com.cn.

Funding

Beijing Municipal Natural Science Foundation Grant No. L222131National Natural Science Foundation of China (NSFC) 82104926
6 · The paper itself

Abstract

objectiveTo elucidate the therapeutic mechanism of Yudantong decoction (YDTD) in cholestatic liver disease (CLD), focusing on the gut microbiota-bile acid-intestinal farnesoid X receptor (FXR) axis.

methodsA CLD mouse model induced by α-naphthylisothiocyanate was treated with YDTD. Hepatic injury, gut microbiota composition (16S rRNA sequencing), bile acid profiles (high-performance liquid chromatography-tandem mass spectrometry, HPLC-MS/MS), intestinal FXR/NLRP3 signaling, and barrier function were assessed. Fecal microbiota transplantation, bile salt hydrolase (BSH) inhibition, and FXR antagonism were employed for mechanistic validation.

resultsCLD mice exhibited hepatocellular steatosis, lobular necrosis, and elevated serum markers. These pathological changes were associated with gut dysbiosis, impaired bile acid metabolism via bile salt hydrolase (BSH) suppression, FXR signaling inhibition, and NLRP3 inflammasome activation. YDTD restored BSH activity and bile acid homeostasis, upregulated FXR expression, suppressed NLRP3 inflammasome activation, and improved intestinal barrier integrity. Fecal microbiota transplantation experiments confirmed that YDTD-modified microbiota mediated these therapeutic benefits, whereas pharmacological inhibition of BSH or FXR attenuated YDTD's therapeutic effects.

conclusionYDTD alleviates CLD, at least in part, by targeting the gut microbiota-bile acid-FXR signaling pathway, highlighting the gut microbiota as a promising therapeutic target for CLD.

Indexed as

Bile Acids and SaltsCholestasisDrugs, Chinese HerbalGastrointestinal MicrobiomeReceptors, Cytoplasmic and NuclearAmidohydrolasesAnimalsDisease Models, AnimalDysbiosisFecal Microbiota TransplantationHumansMaleMiceNLR Family, Pyrin Domain-Containing 3 ProteinReceptor, Farnesoid X-ActivatedSignal TransductionAmidohydrolasesBile Acids and Saltscholoylglycine hydrolaseDrugs, Chinese HerbalNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearBile acidsBile salt hydrolaseCholestatic liver diseaseFecal microbiota trasplantationGut microbiotaIntestinal BarrierIntestinal farnesoid X receptorNLRP3 inflammationYudantong decoction

Identifiers

PMID42053886
PMCPMC13315517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.